{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:56:27Z","timestamp":1791377787411,"version":"4.3.2"},"reference-count":98,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Analytical Chemistry"],"published-print":{"date-parts":[[2024,2,17]]},"DOI":"10.1080\/10408347.2022.2080493","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T18:33:27Z","timestamp":1653590007000},"page":"401-415","source":"Crossref","is-referenced-by-count":6,"title":["Comprehensive Review on Different Analytical Techniques for HIV 1- Integrase Inhibitors: Raltegravir, Dolutegravir, Elvitegravir and Bictegravir"],"prefix":"10.1080","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2801-436X","authenticated-orcid":false,"given":"Priti","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3123-4251","authenticated-orcid":false,"given":"Anusha","family":"Thota","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawan K","family":"Saini","sequence":"additional","affiliation":[{"name":"Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Ghaziabad, UP, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev Singh","family":"Raghuvanshi","sequence":"additional","affiliation":[{"name":"Indian Pharmacopoeia Commission, Ministry of Health and Family Welfare, Ghaziabad, UP, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8493571"},{"key":"e_1_3_2_3_1","unstructured":"National Aids control organization. http:\/\/naco.gov.in\/documents\/policy-guidelines (accessed May 12 2021)."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.236-242.2001"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2001.01380.x"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01534-07"},{"key":"e_1_3_2_7_1","first-page":"595","article-title":"Progress in HIV-1 Integrase Inhibitors: A Review of Their Chemical Structure Diversity","volume":"15","author":"Hajimahdi Z.","year":"2016","unstructured":"Hajimahdi, Z.; Zarghi, A. Progress in HIV-1 Integrase Inhibitors: A Review of Their Chemical Structure Diversity. Iran. J. Pharm. Res. 2016, 15, 595\u2013628.","journal-title":"Iran. J. Pharm. Res."},{"key":"e_1_3_2_8_1","unstructured":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. 2019. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/characteristics-integrase-inhibitors. (accessed Jun 1 2021)."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0015-5"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1010-7"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06407-11"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010387428"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm010253i"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.5599\/admet.850"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04594-14"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.201402393"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.358"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-01995-y"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05739-11"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-409X(00)00130-7"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.4103\/1735-5362.189284"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2013.781153"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0684-z"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052562"},{"key":"e_1_3_2_25_1","first-page":"S217","article-title":"New Analytical Techniques for the Analysis of Raltegravir (Anti-HIV Drug)","volume":"12","author":"Annapurna M. M.","year":"2018","unstructured":"Annapurna, M. M.; Reddy, G. S.; Teja, G. R.; Sri, P. K. P. New Analytical Techniques for the Analysis of Raltegravir (Anti-HIV Drug). Asi J Pharm 2018, 12, S217\u2013S223.","journal-title":"Asi J Pharm"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arabjc.2013.04.016"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diamond.2021.108332"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2013.31026"},{"key":"e_1_3_2_29_1","first-page":"557","article-title":"Spectrophotometric Estimation of Raltegravir Potassium in Tablets","volume":"76","author":"Kore P. P.","year":"2014","unstructured":"Kore, P. P.; Gamepatil, M. M.; Nimje, H. M.; Baheti, K. G. Spectrophotometric Estimation of Raltegravir Potassium in Tablets. Indian J. Pharm. Sci. 2014, 76, 557\u2013559.","journal-title":"Indian J. Pharm. Sci."},{"key":"e_1_3_2_30_1","first-page":"1156","article-title":"Development and Validation of UV Spectrophotometric Method for Estimation of Dolutegravir Sodium in Tablet Dosage Form","volume":"19","author":"Balasaheb B. G.","year":"2015","unstructured":"Balasaheb, B. G.; Balasaheb, A. K.; Subhash, T. R.; Jijabapu, K.; Sudhakar, P. S. Development and Validation of UV Spectrophotometric Method for Estimation of Dolutegravir Sodium in Tablet Dosage Form. Malaysian J. Anal. Sci. 2015, 19, 1156\u20131163.","journal-title":"Malaysian J. Anal. Sci."},{"key":"e_1_3_2_31_1","first-page":"390","article-title":"Comparison of HPLC & Spectrophotometric Methods for Estimation of Antiretroviral Drug Content in Pharmaceutical Products","volume":"132","author":"Hemanth Kumar A. K.","year":"2010","unstructured":"Hemanth Kumar, A. K.; Sudha, V.; Swaminathan, S.; Ramachandran, G. Comparison of HPLC & Spectrophotometric Methods for Estimation of Antiretroviral Drug Content in Pharmaceutical Products. Indian J. Med. Res. 2010, 132, 390\u2013394.","journal-title":"Indian J. Med. Res."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-020-00121-2"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X.2018.00332.3"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.saa.2022.121035"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1556\/1326.2019.00689"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1556\/1006.2018.31.6.9"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.3797\/scipharm.1507-09"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.7324\/JAPS.2013.31026"},{"key":"e_1_3_2_40_1","first-page":"362","article-title":"UPLC Separation Analysis of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir from Their Degradation Products","volume":"8","author":"Lakshmi R. N.","year":"2016","unstructured":"Lakshmi, R. N.; Prahlad, P.; Mastanammas, S. K.; Ravindra, N.; Venkatabasaveswara rao, M. UPLC Separation Analysis of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir from Their Degradation Products. Int. J. Pharm. Pharm. Sci. 2016, 8, 362\u2013369.","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.53879\/id.56.10.11796"},{"key":"e_1_3_2_42_1","first-page":"P90","article-title":"Stability Indicating RP-UPLC Method for Simultaneous Estimation of Emtricitabine, Tenofovir and Bictegravir in Bulk and Pharmaceutical Dosage Form","volume":"10","author":"Konam K.","year":"2020","unstructured":"Konam, K.; Abdul Rahaman, S. K. Stability Indicating RP-UPLC Method for Simultaneous Estimation of Emtricitabine, Tenofovir and Bictegravir in Bulk and Pharmaceutical Dosage Form. Int. J. Life Sc. Ph. Res. 2020, 10, P90\u2013101.","journal-title":"Int. J. Life Sc. Ph. Res."},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2008.12.038"},{"key":"e_1_3_2_44_1","first-page":"195","article-title":"A Rapid Validated UV-HPLC Method for the Simultaneous Determination of the Antiretroviral Compounds Darunavir and Raltegravir in Their Dosage Form","volume":"30","author":"Estan-Cerezo G.","year":"2017","unstructured":"Estan-Cerezo, G.; Garcia-Monsalve, A.; Soriano-Irigaray, L.; Rodriguez-Lucena, F. J.; Navarro-Ruiz, A. A Rapid Validated UV-HPLC Method for the Simultaneous Determination of the Antiretroviral Compounds Darunavir and Raltegravir in Their Dosage Form. Rev. Esp. Quimioter. 2017, 30, 195\u2013200.","journal-title":"Rev. Esp. Quimioter."},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000286"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.06.009"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000290"},{"key":"e_1_3_2_48_1","first-page":"217","article-title":"Validated Reverse Phase HPLC Method for Determination of Raltegravir in Pharmaceutical Preparation","volume":"2","author":"Lakshamana Rao A.","year":"2012","unstructured":"Lakshamana Rao, A.; Raghu Ram, M. S. Validated Reverse Phase HPLC Method for Determination of Raltegravir in Pharmaceutical Preparation. Int. J. Res. Pharm. Chem. 2012, 2, 217\u2013221.","journal-title":"Int. J. Res. Pharm. Chem."},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.5530\/phm.2014.1.2"},{"key":"e_1_3_2_50_1","first-page":"3584","article-title":"A New Simple Analytical Method for Simultaneous Estimation of Cobicistat and Elvetigravir by RP-HPLC-PDA in Their Tablet Dosage Forms","volume":"8","author":"Ganta S.","year":"2017","unstructured":"Ganta, S.; Vidyadhara, S. A New Simple Analytical Method for Simultaneous Estimation of Cobicistat and Elvetigravir by RP-HPLC-PDA in Their Tablet Dosage Forms. J Glob Trends Pharm. 2017, 8, 3584\u20133589.","journal-title":"J Glob Trends Pharm."},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.5530\/jyp.2019.11.55"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/chromsci\/bmw004"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4274"},{"key":"e_1_3_2_54_1","first-page":"158","article-title":"Determination of Simultaneous Estimation HPLC Method for Elvitegravir, Tenofovir Disoproxil Fumarate, Emtricitabine and Cobicistat It\u2019s Pure and Tablet Form","volume":"10","author":"Godasu S. K.","year":"2018","unstructured":"Godasu, S. K.; Sreenivas, S. A. Determination of Simultaneous Estimation HPLC Method for Elvitegravir, Tenofovir Disoproxil Fumarate, Emtricitabine and Cobicistat It\u2019s Pure and Tablet Form. Der Pharma Chemica. 2018, 10, 158\u2013165.","journal-title":"Der Pharma Chemica."},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.4172\/pharmaceutical-sciences.1000148"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fjps.2015.11.002"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.22159\/ajpcr.2019.v12i2.29669"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.13040\/IJPSR.0975-8232.11(10).4991-97"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X.2020.00510.7"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-020-00026-0"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s43094-020-00060-y"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.12973\/EJAC.2017.00162A"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.22034\/IJPS.2018.91032.1465"},{"key":"e_1_3_2_64_1","first-page":"11","article-title":"Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Dolutegravir and Rilpivirine in Bulk and Pharmaceutical Dosage Form","volume":"62","author":"Raj Kumar B.","year":"2020","unstructured":"Raj Kumar, B.; Subrahmanyam, K. V. Stability-Indicating RP-HPLC Method for the Simultaneous Determination of Dolutegravir and Rilpivirine in Bulk and Pharmaceutical Dosage Form. Int J Pharm Sci Res Res. 2020, 62, 11\u201316.","journal-title":"Int J Pharm Sci Res Res."},{"key":"e_1_3_2_65_1","first-page":"7123","article-title":"Method Development and Validation by RP-HPLC for Simultaneous Estimation of Emtricitabine, Bictegravir, Tenofovir Alafenamide in Fixed Dosage Form","volume":"05","author":"Meenakshi R.","year":"2018","unstructured":"Meenakshi, R.; Shyam Sunder, R. Method Development and Validation by RP-HPLC for Simultaneous Estimation of Emtricitabine, Bictegravir, Tenofovir Alafenamide in Fixed Dosage Form. Indo Am J P Sci. 2018, 05, 7123\u20137131.","journal-title":"Indo Am J P Sci."},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1080\/16583655.2019.1689601"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.3261393"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.13040\/IJPSR.0975-8232.10(11).4981-87"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.5530\/ijper.50.1.25"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.37591\/rrjodfdp.v5i2.128"},{"key":"e_1_3_2_71_1","first-page":"1","article-title":"Reverse Phase High Performance Liquid Chromatography and Ultra Violet Spetrophotometric Method for the Estimation of Raltegravir Potassium in Bulk and in Tablet Dosage Form","volume":"11","author":"Sudha T.","year":"2011","unstructured":"Sudha, T.; Raghupathi, T. Reverse Phase High Performance Liquid Chromatography and Ultra Violet Spetrophotometric Method for the Estimation of Raltegravir Potassium in Bulk and in Tablet Dosage Form. Glob J Med Res. 2011, 11, 1\u20139.","journal-title":"Glob J Med Res."},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216-018-1394-y"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2018.12.008"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.4506"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac303188j"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2016.05.040"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2012.05.035"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.3200"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.12.034"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e318280110d"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.2011.01368.x"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2012.12.028"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2015.06.005"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2013.11.054"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2016.07.040"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.1874"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac301581h"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4058"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aca.2019.01.015"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2013.09.006"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017.02.002"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113250"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149225"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.112838"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.4379"},{"key":"e_1_3_2_96_1","first-page":"441","article-title":"Bioanalytical Method Development and Validation for Simultaneous Determination of Bictegravir, Tenofovir and Emtricitabine in Human Plasma by LCMS\/MS","volume":"7","author":"Appala Raju V. V. S. S.","year":"2018","unstructured":"Appala Raju, V. V. S. S.; Ramana, M. V.; Shyam, T.; Rajinikanth, K. N.; Kiran Kumar, V.; Appala Raju, N. Bioanalytical Method Development and Validation for Simultaneous Determination of Bictegravir, Tenofovir and Emtricitabine in Human Plasma by LCMS\/MS. World J Pharm Pharm Sci. 2018, 7, 441\u2013463.","journal-title":"World J Pharm Pharm Sci."},{"key":"e_1_3_2_97_1","doi-asserted-by":"publisher","DOI":"10.22159\/ijcpr.2017v9i5.22151"},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.35248\/2157-7064.20.11.426"},{"key":"e_1_3_2_99_1","first-page":"685","article-title":"Development and Validation of Forced Degradation Studies of Raltegravir Using RP-HPLC and Characterization of Degradants by LC-MS\/MS","volume":"7","author":"Bhavyasri K.","year":"2015","unstructured":"Bhavyasri, K.; Balaram, V. M.; Nageswarao, R.; Rambabu, D.; Ajitha, M. Development and Validation of Forced Degradation Studies of Raltegravir Using RP-HPLC and Characterization of Degradants by LC-MS\/MS. Int. J. Chem. Sci. 2015, 7, 685\u2013689.","journal-title":"Int. J. Chem. Sci."}],"container-title":["Critical Reviews in Analytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10408347.2022.2080493","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T17:10:09Z","timestamp":1709140209000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10408347.2022.2080493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":98,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2,17]]}},"alternative-id":["10.1080\/10408347.2022.2080493"],"URL":"https:\/\/doi.org\/10.1080\/10408347.2022.2080493","relation":{},"ISSN":["1040-8347","1547-6510"],"issn-type":[{"value":"1040-8347","type":"print"},{"value":"1547-6510","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]}}}